| 4.64 -0.16 (-3.33%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.71  |
1-year : | 6.67 |
| Resists | First : | 4.88 |
Second : | 5.71 |
| Pivot price | 3.58 |
|||
| Supports | First : | 3.36 |
Second : | 2.42 |
| MAs | MA(5) : | 4.2 |
MA(20) : | 3.46 |
| MA(100) : | 2.25 |
MA(250) : | 1.51 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 92.5  |
D(3) : | 92.6 |
| RSI | RSI(14): 83.2 |
|||
| 52-week | High : | 4.88 | Low : | 0.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STTK ] has closed below upper band by 1.4%. Bollinger Bands are 154.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.89 - 4.92 | 4.92 - 4.93 |
| Low: | 4.44 - 4.48 | 4.48 - 4.5 |
| Close: | 4.59 - 4.64 | 4.64 - 4.67 |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Tue, 06 Jan 2026
Shattuck Labs (STTK): Citigroup Maintains Neutral Rating, Raises Price Target | STTK Stock News - GuruFocus
Mon, 05 Jan 2026
Shattuck Labs (STTK) Stock Soars 74% Following Analyst Upgrade to Buy - Intellectia AI
Mon, 05 Jan 2026
Why Shattuck Labs Stock Soared in December - Finviz
Tue, 30 Dec 2025
Shattuck Labs, Inc.'s (NASDAQ:STTK) biggest owners are retail investors who got richer after stock soared 10% last week - Sahm
Tue, 16 Dec 2025
Shattuck Labs (NASDAQ:STTK) Shares Down 1.3% - Time to Sell? - MarketBeat
Mon, 15 Dec 2025
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 3.254e+007 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 893 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.383e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 71.5 % |
| Return on Equity (ttm) | -34 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | -38.95 |
| Sales Per Share | -33.83 |
| EBITDA (p.s.) | 1.26901e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 5.36 |
| Dividend | 0 |
| Forward Dividend | 742540 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|